Results 161 to 169 of about 2,912 (169)

Is meropenem–vaborbactam as effective as usual antibiotics in patients with serious infections?

Evidence-Based Practice, 2019
Joy C. Anyanwu, Edward Foley
openaire   +1 more source

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2018
Olga Lomovskaya, , Mojgan Sabet
exaly  

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam

Antimicrobial Agents and Chemotherapy, 2018
Jason Roberts, Steven Wallis
exaly  

Pharmacokinetics of the Meropenem Component of Meropenem‐Vaborbactam in the Treatment of KPC‐Producing Klebsiella pneumoniae Bloodstream Infection in a Pediatric Patient

Pharmacotherapy, 2018

exaly  

In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China

Journal of Antimicrobial Chemotherapy, 2018
Qiwen Yang, Olga Lomovskaya, Ge Zhang
exaly  

In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance

Diagnostic Microbiology and Infectious Disease, 2019
Erin Mccreary, , Barry C Fox
exaly  

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations

Clinical Infectious Diseases, 2019
Robert Bonomo
exaly  

P241 Safety and efficacy of meropenem-vaborbactam in people with cystic fibrosis (pwCF)

Journal of Cystic Fibrosis
M. Abdalaziz, H. Saumtally, G. Spoletini, E. Williams, C. Etherington, I. Clifton, M. Denton, D. Peckham   +7 more
openaire   +1 more source

Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection.

The Medical letter on drugs and therapeutics, 2018
openaire   +1 more source